This microchip could demystify the nervous system
The nervous system is a real biological wonder. Just think about everything it’s responsible for: our ability to move, breathe, see, think. But as important and widely studied as it is, fully understanding the nervous system has been pretty elusive.
When it comes to treating nerve issues, our abilities have traditionally been very limited. Why? Physicians don’t have the tools to sense, target, or influence neuronal signals in a safe and reliable way. So instead, they’ve been using the approach they jokingly refer to as “treat and pray,” which is exactly as it sounds—not ideal for high-stakes medical diagnoses.
That’s where a company called Autonomix comes in. Their technology, which uses the same electronic form factor found in smartwatches, could change the way pain is diagnosed and treated by providing clearer visibility into the nervous system. That visibility allows physicians to potentially pinpoint and treat nerves in problem areas.
Picture a suitcase-sized piece of equipment. Autonomix aims to shrink that down to the size of a 1- to 2-millimeter microchip (no bigger than the head of a pin 🤯). At that size, the sensing technology they’re developing is small enough to travel into the cardiovascular system with extremely high sensitivity. And that’s a pretty big deal, as it would provide access to the nerves throughout the body.
This level of sensing technology is thousands of times more sensitive than the best equipment on the market today. It means the end of the “treat and pray” approach (hallelujah), and it opens up new treatment opportunities for all kinds of conditions: hypertension, pulmonary disorders, pain management, digestive disorders, and more. With so many potential use cases, it’s no surprise that Autonomix is looking at an estimated $110b worldwide market opportunity.
The brains behind this neural technology know a thing or two about MedTech. They have a track record of building medical companies and technologies that have created billions in value for companies like AbbVie and Boston Scientific.
With over 100 patents either issued or pending, Autonomix is gearing up to scale. And they’re currently open to investors who want to get involved in their innovative tech at an early stage. Once the funding round ends, it’s planned to be off to Nasdaq.
If Autonomix tracks the way similar companies in their industry have, there’s some big-time exit potential. Medtronic, Boston Scientific, and others have spent as much as $900m on individual acquisitions in the industry.
With great potential comes great opportunity. Learn how you can join Autonomix on their mission to revolutionize our understanding of the human nervous system.
Download the Autonomix Investor Deck
